Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK ...
The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...
The PRAETORIAN score is a noninvasive test that gives a score from 30 to 900, which can be interpreted as low risk (<90 ...
Restarting subcutaneous infliximab 240 mg after treatment interruption of at least 16 weeks was able to recapture response ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentCLYM116 modeling ...
Discover how subcutaneous melanoma immunotherapy replaces IV infusions, cutting clinic time while delivering the same proven ...
AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...
Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentBudoprutug pMN, ...
AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...
A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results